• Title/Summary/Keyword: Beevenom Pharmacopuncture

Search Result 3, Processing Time 0.023 seconds

Clinical Study of Twenty-seven Case of Treating Acne scar Using Microneedle Therapy and Subcision Combined with Beevenom Pharmacopuncture Therapy (미세피부침, 절개침법과 봉독 약침 복합 요법의 여드름 흉터 치료 27례 임상 보고)

  • Kim, Hye-Yoon;Hong, Seok-Hoon;Park, In-Hae;Heo, Eun-Sun;Noh, Hyeon-Min;Shin, Sun-Ho
    • The Journal of Korean Medicine Ophthalmology and Otolaryngology and Dermatology
    • /
    • v.28 no.3
    • /
    • pp.101-113
    • /
    • 2015
  • Objectives : Microneedle therapy and Subcision are commonly used for therapeutic modalities of acne scars in Korean medicine. Beevenom could promote the expression of various cytokines, enzymes and receptors related to increasing collagen content of connective tissues. Through this mechanism, we considered that Beevenom pharmacopuncture therapy is applicable to the treatment of acne scars. We investigated twenty-seven patients with acne scars treated by Microneedle therapy and Subcision combined with Beevenom pharmacopuncture therapy and evaluated the clinical effect.Methods : Twenty-seven patients with acne scars were treated by Microneedle therapy and Subcision combined with Beevenom pharmacopuncture therapy and evaluated the clinical effect. for twelve weeks. The severity of acne scars and treatment effect were evaluate by standardized photography, GASC, ECCA scale and patient`s satisfaction. And side effects was also checked.Results : After twelve weeks for treatment, there was an improvement in GASC, ECCA scale. 77.8% of patient replied excellent or good on patient satisfaction survey. One patient sufferied from pruritus, papules and comedones as side effect of treatment.Conclusion : It can be considered that Microneedle, Subcision, Beevenom pharmacopuncture combining therapy are effective method for treating acne scars.

Immunological Changes on Allergic Response after Beevenom Immunotherapy (봉독 면역요법후의 면역학적 변화에 대한 고찰 -알레르기 질환에 응용 가능성을 중심으로-)

  • Han, Dong-Ha
    • Journal of Pharmacopuncture
    • /
    • v.7 no.3
    • /
    • pp.27-35
    • /
    • 2004
  • Beevenom immunotherapy(BVIT) in allergic patients is a well-established treatment modality for the prevention of systemic anaphylactic reactions caused by insect stings. BVIT is accompanied by increases in allergen-specific IgG, particularly the IgG4 isotype, which blocks not only IgE-dependent histamine release from basophils but also IgE-mediated antigen presentation to T cells. Inhibition of T cells after BVIT also involves decreased induction of the costimulatory molecule ICOS, which, in turn, seems to be dependent on the presence of IL-10, also associated with the inhibited status of T cells after BVIT. Suppression of T cells by IL-10 is an active process, which depends on the expression and participation of CD28. Immune tolerance in specific allergen immunotherapy might be a consequence of decreased Th2 or increased Th1 response of allergen specific T lymphocytes. BVIT shifted cytokine responses to allergen from a TH-2 to a TH-1 dominant pattern, suggesting direct effects on T cells. Many studies showed that severe side effects due to venom immunotherapy are rare. These results suggest that immunological changes after BVIT may be applied to be therapeutic alternative of general allergic diseases including beevenom allergy.

The Current Research Methodology of Pharmacopucture for the Treatment of Animal Cancer Models in Korea (암에 대한 약침치료의 국내 동물모델 연구 현황)

  • Ryu, Hee Kyoung;Goo, Bon Hyuk;Suk, Kyung Hwan;Lee, Ju Hyeon;Ryu, Soo Hyeong;Lee, Su Yeon;Kim, Min Jeong;Park, Yeon Cheol;Baek, Yong Hyeon;Park, Dong Suk;Seo, Byung Kwan
    • Journal of Acupuncture Research
    • /
    • v.31 no.4
    • /
    • pp.81-97
    • /
    • 2014
  • Objectives : The purpose of this study is analyzing the current research methodology of pharmacopucture for the treatment of animal cancer models. Methods : Four electronic databases were searched for animal studies published from January 2000 to September 2014 onward using these search terms "cancer, anticancer, pharmacopuncture, beevenom". Selected articles were described about animal cancer models. The methods used to induce cancer and the outcome measures used to assess the effects of pharmacopuncture on animal cancer models were analyzed. Results : 37 articles were included. For producing animal cancer models BALB/C mice(n=22) and C57BL/6 mice(n=17) were selected. And intravenous injection of B16-F10 melanoma cells into tail vein(n=14) or intraperitoneal injection of sarcoma-180 cells(n=14) were frequently used to induce cancer. Various pharmacopunctures were injected into acupoints $CV_{12}(n=19)$, $ST_{36}(n=8)$, $BL_{18}(n=8)$ or peritoneal cavity(n=6), tumor site(n=2), tail vein(n=2). Outcome measures were categorized into anti-cancer, anti-metastasis, general condition, cytotoxicity, immune response, toxicity. Median Survival Time(MST) and increase of life span(ILS)(n=26) was frequently used for evaluating anti-cancer effects. And pulmonary colonization assay(n=13) was frequently used for evaluating anti-metastasis effects Conclusions : Based on these data, further research would be needed to ascertain the effectiveness of pharmacopuncture for treating cancer and broaden the range of clinical applications.